A comparison of rezafungin and caspofungin for the treatment of candidemia and invasive candidiasis found that rezafungin may offer an early treatment benefit with its front-loaded dosing regimen. Study findings published in The Lancet Infectious Diseases showed that rezafungin was noninferior to caspofungin in terms of all-cause mortality and had higher rates of mycologic eradication. Patients in the rezafungin group also had fewer treatment-emergent adverse events. The availability of rezafungin as a new antifungal is a valuable addition to candidemia and invasive candidiasis treatments and may help to address the growing challenge of treatment-resistant Candida strains and species. This research was supported by Melinta Therapeutics and Cidara Therapeutics, with multiple study authors declaring affiliations with industry.
Source link
Rezafungin May Provide Early Treatment Benefit in Candidemia, Invasive Candidiasis
